Multimodal therapeutic approach and interdisciplinary challenge for the treatment of unresectable head and neck squamous cell carcinoma in six cats: A pilot study

Veterinary and Comparative Oncology

Volumn 11, Issue 2, 2013, Pages 101-112

  Marconato, L ^a   Buchholz, J ^a   Keller, M ^b   Bettini, G ^c   Valenti, P ^a   Kaser Hotz, B ^a  

^a Animal Oncology and Imaging Center   (Switzerland)

^b Tierärztliche Spezialistenklinik ^*  (Switzerland)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Accelerated hypofractionated radiation therapy; Anti angiogenesis; Feline; Head and neck; SCC

Indexed keywords

ANIMAL; ANIMAL DISEASE; ARTICLE; CAT; CAT DISEASE; FEMALE; HEAD AND NECK TUMOR; MALE; PILOT STUDY; RADIOTHERAPY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CAT DISEASES; CATS; FEMALE; HEAD AND NECK NEOPLASMS; MALE; PILOT PROJECTS; RADIOTHERAPY; TREATMENT OUTCOME;

FELIDAE;

EID: 84877628642     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2011.00304.x     Document Type: Article

References (40)

1. Stebbins KE, Morse CC and Goldschmidt MH. Feline oral neoplasia: a ten-year survey. Veterinary Pathology 1989; 26: 121-128.
2. Reeves NC, Turrel JM and Withrow SJ. Oral squamous cell carcinoma in the cat. Journal of the American Animal Hospital Association 1993; 29: 438-441.
3. Herring ES, Smith MM and Robertson JL. Lymph node staging of oral and maxillofacial neoplasms in 31 dogs and cats. Journal of Veterinary Dentistry 2002; 19: 122-126.
4. Northrup NC, Selting KA, Rassnick KM, Kristal O, O'Brien MG, Dank G, Dhaliwal RS, Jagannatha S, Cornell KK and Gieger TL. Outcomes of cats with oral tumors treated with manidubelctomy: 42cases. Journal of the American Animal Hospital Association 2006; 42: 350-360.
5. Bradley RL, MacEwen EG and Loar AS. Mandibular resection for removal of oral tumors in 30 dogs and 6cats. Journal of the American Veterinary Medical Association 1984; 184: 460-463.
6. Bradley RL, Sponenberg DP and Martin RA. Oral neoplasia in 15 dogs and four cats. Seminars in Veterinary Medicine Surgery (Small Animal) 1986; 1: 33-42.
7. Penwick RC and Nunamaker DM. Rostral mandibulectomy: a treatment for oral neoplasia in the dog and cat. Journal of the American Animal Hospital Association 1987; 23: 19-25.
8. Hayes AM, Adams VJ, Scase TJ and Murphy S. Survival of 54cats with oral squamous cell carcinoma in United Kingdom general practice. Journal of Small Animal Practice 2007; 48: 394-399.
9. Bregazzi VS, LaRue SM, Powers BE, Fettman MJ, Ogilvie GK and Withrow SJ. Response of feline oral squamous cell carcinoma to palliative radiation therapy. Veterinary Radiology & Ultrasound 2001; 42: 77-79.
10. Evans SM, LaCreta F, Helfand S, VanWinkle T, Curran WJ Jr, Brown DQ and Hanks G. Technique, pharmacokinetics, toxicity, and efficacy of intratumoral etanidazole and radiotherapy for treatment of spontaneous feline oral squamous cell carcinoma. International Journal of Radiation Oncology, Biology, Physics 1991; 20: 703-708.
11. Fidel JL, Sellon RK, Houston RK and Wheeler BA. A nine-day accelerated radiation protocol for feline squamous cell carcinoma. Veterinary Radiology & Ultrasound 2007; 48: 482-485.
12. Mauldin GN, Matus RE, Patnaik AK, Bond BR and Mooney SC. Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23cats. Journal of Veterinary Internal Medicine 1988; 2: 60-65.
13. Kisseberth WC, Vail DM, Yaissle J, Jeglum KA, Couto CG, Ward H, Khanna C and Obradovich JE. Phase I clinical evaluation of carboplatin in tumor-bearing cats: a Veterinary Cooperative Oncology Group study. Journal of Veterinary Internal Medicine 2008; 22: 83-88.
14. Ogilvie GK, Moore AS, Obradovich JE, Elmslie RE, Vail DM, Straw RC, Salmon MD, Klein MK, Atwater SW and Ciekot PE. Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors. Journal of the American Veterinary Medical Association 1993; 202: 1839-1844.
15. Wood C. Combination coarse fractionation radiation therapy and carboplatin chemotherapy for treatment of feline oral squamous cell carcinoma: an interim analysis. VCS Newsletter 1998; 22: 1-4.
16. Jones PD, de Lorimier LP, Kitchell BE and Losonsky JM. Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma. Journal of the American Animal Hospital Association 2003; 39: 463-467.
17. LeBlanc AK, LaDue TA, Turrel JM and Klein MK. Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: a Veterinary Radiation Therapy Oncology Group pilot study. Veterinary Radiology & Ultrasound 2004; 45: 466-670.
18. Owen LN. TNM Classification of Tumors in Domestic Animals. Geneva, World Health Organization, 1980.
19. Veterinary Cooperative Oncology Group. Veterinary Cooperative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2004; 2: 194-213.
20. Ladue T, Klein MK and Veterinary Radiation Therapy Oncology Group. Toxicity criteria of the veterinary radiation therapy oncology group. Veterinary Radiology & Ultrasound 2001; 42: 475-476.
21. Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 2005; 55: 74-108.
22. Jemal A, Murray T and Ward E. Cancer statistics, 2005. CA: A Cancer Journal for Clinicians 2005; 55: 10-30.
23. Haddad RI and Shin DM. Recent advances in head and neck cancer. New England Journal of Medicine 2008; 359: 1143-1154.
24. Barasch A, Safford M and Eisenberg E. Oral cancer and oral effects of anticancer therapy. Mount Sinai Journal of Medicine 1998; 65: 370-377.
25. MacEwen EG. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Reviews 1990; 9: 125-136.
26. Hayes HM. The comparative epidemiology of selected neoplasms between dogs, cats and humans. A review. European Journal of Cancer 1978; 14: 1299-1308.
27. Vail DM and MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Investigation 2000; 18: 781-792.
28. Paoloni M and Khanna C. Comparative oncology today. Veterinary Clinics of North America. Small Animal Practice 2007; 37: 1023-1032.
29. Tannehill-Gregg SH, Levine AL and Rosol TJ. Feline head and neck squamous cell carcinoma: a natural model for the human disease and development of a mouse model. Veterinary and Comparative Oncology 2006; 4: 84-97.
30. Buhles WC Jr. and Theilen GH. Preliminary evaluation of bleomycin in feline and canine squamous cell carcinoma. American Journal of Veterinary Research 1973; 34: 289-291.
31. DiBernardi L, Doré M, Davis JA, Owens JG, Mohammed SI, Guptill CF and Knapp DW. Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment. Prostaglandins Leukot Essent Fatty Acids 2007; 76: 245-250.
32. Bulman-Fleming JC, Turner TR and Rosenberg MP. Evaluation of adverse events in cats receiving long-term piroxicam therapy for various neoplasms. Journal of Feline Medicine and Surgery 2010; 12: 262-268.
33. Riggs CE. Antitumor antibiotics and related compounds. In: The Chemotherapy Source Book, 3rd edn., MC Perry, ed., Philadelphia, Lippincott Williams & Wilkins, 2001: 237-239.
34. Hayes A, Scase T, Miller J, Murphy S, Sparkes A and Adams V. COX-1 and COX-2 expression in feline oral squamous cell carcinoma. Journal of Comparative Pathology 2006; 135: 93-99.
35. Kenyon BM, Browne F and D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Experimental Eye Research 1997; 64: 971-978.
36. Porter SR and Jorge J Jr. Thalidomide: a role in oral oncology? Oral Oncology 2002; 38: 527-531.
37. Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK and Herbst RS. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 2001; 92: 2364-2373.
38. Myoung H, Hong SD, Kim YY, Hong SP and Kim MJ. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Letters 2001; 163: 191-200.
39. Schwyn U, Crompton NE, Blattmann H, Hauser B, Klink B, Parvis A, Ruslander D and Kaser-Hotz B. Potential tumour doubling time: determination of Tpot for various canine and feline tumours. Veterinary Research Communications 1998; 22: 233-247.
40. Hall EJ. Time, dose, and fractionation in radiotherapy. In: Radiobiology for the Radiologists, 6th edn., EJ Hall and AJ Giaccia, eds., Philadelphia, PA, Lippincott William & Wilkins, 2000: 378-397.